OnCo
peoplePerson

Nicholas James

Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.

Nicholas James leads STAMPEDE, the multi-arm multi-stage trial that established docetaxel and abiraterone in hormone-sensitive metastatic prostate cancer, and has led trials of chemoradiotherapy in bladder cancer.

Role
Professor of Prostate and Bladder Cancer Research, ICR; Consultant Clinical Oncologist, Royal Marsden
Specialisms
Prostate cancerBladder cancerMulti-arm platform trialsRadiotherapy
Profiles

Papers

1top
TitleJournalYear
Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)NEJM2017

Key papers

1top
rctNew England Journal of Medicine 2017changed practice
STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer

Men diagnosed with prostate cancer that has already spread, or that is locally advanced and high risk, should start abiraterone (or another androgen-receptor pathway inhibitor) at the same time as testosterone suppression rather than waiting for resistance. This roughly halves the risk of death over several years. The same platform later showed that docetaxel chemotherapy and, in high-volume metastatic disease, triple therapy also help, and that abiraterone benefits men with high-risk disease treated with radiotherapy.

Connected

10top

cancers

2
Bladder & urothelial cancerProstate cancer

drugs

2
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
ApprovedCytotoxic chemotherapy (taxane)
Docetaxel · Taxotere (generic)

institutions

3
The Institute of Cancer ResearchThe Royal MarsdenUniversity College London Hospitals / UCL Cancer Institute

terms

1
Basket, umbrella, and platform trials

trials

1
STAMPEDE

key papers

1
STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer